Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • ACCESS: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide for Patients with Hematologic Malignancies

    Cancer Categories
    • Hematologic (Blood Cancers)
    Karmanos Trial ID
    • 2021-029
    NCT ID
    • NCT04904588
    Age Group
    • Adult
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase II
    Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
    • Phase II
    Principal Investigator
    • Dipenkumar
      Modi, M.D.

      Oncology - Hematology, Oncology - Medical View Profile


    Primary Objective:

    • To determine OS at one year following transplantation of a PBSC product from a MMUD using PTCy based GVHD prophylaxis

    Secondary Objectives:

    • To determine the incidence of CRS within 14 days of HCT
    • To determine event-free survival (EFS) at 1-year (events include graft failure, relapse,
      death, National Institutes of Health [NIH]-severe cGvHD, and grade 3-4 aGvHD.
    • To determine GRFS and modified GRFS (mGRFS) at 1-year post-HCT
    • To determine progression-free survival (PFS) at 1-year post-HCT
    • To determine NRM at Day+100 and 1-year post-HCT
    • To determine EFS and OS at 1 year based on donor HLA Match grade and donor age
      (7/8 versus <7/8)
    • To determine cumulative incidence and kinetics of neutrophil recovery
    • To determine cumulative incidence and kinetics of platelet recovery
    • To determine cumulative incidence of primary and secondary graft failure
    • To determine donor chimerism at day +100 (Strata 2 and 3)
    • To determine cumulative incidences of aGVHD and cGVHD
    • To determine cumulative incidence of relapse/progression
    • To determine cumulative incidence of BK and CMV viral infections
  • Locations


    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266